Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03795012
Other study ID # MedOPP167
Secondary ID 2017-004324-30
Status Terminated
Phase Phase 2
First received
Last updated
Start date April 30, 2019
Est. completion date March 31, 2021

Study information

Verified date August 2021
Source MedSIR
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Unresectable, ER-positive and/or PR-positive and HER2-negative locally-recurrent or metastatic breast cancer (mBC).


Description:

Pre- and post-menopausal women age ≥ 18 years with unresectable, ER-positive and/or PR-positive and HER2-negative locally-recurrent or metastatic breast cancer (mBC) with no prior line of chemotherapy in the metastatic setting, and that have shown progression while on an aromatase inhibitor-containing regimen in the metastatic setting or within six months from last aromatase inhibitor dose in the adjuvant setting. Patients must have received at least one taxane or anthracycline regimen in either the adjuvant or the neoadjuvant setting. Subjects must have adequate bone marrow and creatinine clearance functions.


Recruitment information / eligibility

Status Terminated
Enrollment 22
Est. completion date March 31, 2021
Est. primary completion date March 31, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - ER-positive and/or PR-positive breast cancer. - HER2-negative breast cancer. - Unresectable locally advanced or metastatic breast cancer. - Confirmed disease progression while in the last aromatase inhibition-containing regimen in the metastatic setting. - At least one taxane or anthracycline regimen in either the adjuvant or the neoadjuvant setting. - Patients with no prior line of chemotherapy in the metastatic setting. - At least 1 and up to 3 prior lines of endocrine therapy in the metastatic setting. - ECOG score 0 or 1. - Patients have adequate bone marrow and organ function. - Patients must have measurable disease (RECIST v.1.1). - Premenopausal with LHRH analogues for at least 28 days) and postmenopausal women. - Patients must agree to not breastfeed during the study and for 3 months after the last dose of study treatment. - Life expectancy greater or equal to 12 weeks. - Patients agree to collection of blood samples (liquid biopsy) and optional collection of metastatic tumour sample (biopsy) at the time of inclusion and progression (if appropriate). Exclusion Criteria: - Have received radiation therapy or limited-field palliative radiotherapy within two weeks prior to Cycle 1, Day 1, or patients who have not recovered from radiotherapy-related toxicities. - Have received prior chemotherapy for locally advanced or metastatic disease. - Have peripheral neuropathy grade 2 or greater. - QTc > 480 msec on basal assessments, history of congenital or personal history of long QT syndrome, Brugada syndrome, or Torsade de Pointes (TdP), or uncontrolled electrolyte disorders - Child-bearing potential women not using highly effective methods of contraception. - Known hypersensitivity to eribulin, endocrine therapy or its excipients. - Other malignancies within the previous two years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of cervix or breast. - Known uncontrolled metastases to the central nervous system (CNS) or any progressing CNS disease. - Have a serious concomitant systemic disorder incompatible with the study. - Major surgical procedure or significant traumatic injury within 28 days prior to randomization. - Have received any anti-cancer biology or investigational treatment within 30 days prior to randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Eribulin
Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.

Locations

Country Name City State
Spain Hospital Quiron Dexeus Barcelona Please Select
Spain Institut Català d'Oncologia Girona
Spain Hospital de Jaén Jaen Jaén
Spain Complejo Asistencial Universitario de León León
Spain Hospital Ramón y Cajal Madrid
Spain Hospital Universitario La Paz, Madrid
Spain Hospital Son Llatzer Palma De Mallorca
Spain Hospital Universitario Dr Peset Valencia
Spain Hospital Miguel Servet Zaragoza

Sponsors (1)

Lead Sponsor Collaborator
MedSIR

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The overall response rate (ORR) The overall response rate (ORR) in the eribulin + ET arms, defined as the proportion of patients with best overall response of confirmed complete response or partial response based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11. Baseline up to 27 months
Secondary The progression-free survival (PFS) The progression-free survival (PFS) for patients treated with endocrine therapy alone or in combination with eribulin is defined as the time from randomization until death by any cause or objective tumor progression based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11. Baseline up to 27 months
Secondary PFS-2, in the eribulin and the eribulin + ET arms The PFS-2, in the eribulin and the eribulin + ET arms, defined as the time from the randomization to the second disease progression or death, i.e., PFS after the next line of treatment, based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11. Baseline up to 27 months
Secondary Overall response rate (ORR) in the eribulin arm The overall response rate (ORR) in the eribulin arm, defined as the proportion of patients with best overall response of confirmed complete response or partial response based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11. Baseline up to 27 months
Secondary The duration of response (DOR) in the eribulin and the eribulin + ET arms The duration of response (DOR) in the eribulin and the eribulin + ET arms, defined as the time from the start of the treatment to disease progression based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11. Baseline up to 27 months
Secondary The clinical benefit rate (CBR) in the eribulin and the eribulin + ET arms The clinical benefit rate (CBR) in the eribulin and the eribulin + ET arms, defined as the proportion of patients with no disease progression after 6 months of therapy, based on local investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria v. 1.11. Baseline up to 27 months
Secondary The overall survival (OS) in the eribulin and the eribulin + ET arms The overall survival (OS) in the eribulin and the eribulin + ET arms, defined as the length of time that patients remain alive from the start of treatment (OS will be collected at the end of the study). Baseline up to 27 months
Secondary Maximum Tumor shrinkage Maximum Tumor shrinkage, defined as the percentage of tumor shrinkage from baseline (obtained from the sum of the largest diameters of the target lesions), based on local investigator's assessment according to RECIST criteria guidelines (version 1.1)1. Baseline up to 27 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2